Michael Yang

Mr. Yang brings over 30 years of biopharmaceutical executive experience from roles that range from CEO of a privately held, clinical stage company to President of large enterprises generating billion-dollar revenue platforms. Mr. Yang is an operating partner of Artis Ventures, serving on several boards across the Artis portfolio. He most recently served as President and Chief Executive Officer of ViaCyte, which was acquired by Vertex in 2022. Prior to ViaCyte, Mr. Yang was Executive Vice President and Chief Commercial Officer at Acadia Pharmaceuticals (Nasdaq: ACAD) During his tenure, Acadia transformed the standard of care for patients with Parkinson’s disease psychosis. Prior to Acadia, Mr. Yang was President of Janssen Biotech Inc., a Johnson & Johnson (NYSE: JNJ) company, where he was responsible for building Janssen’s U.S. immunology business, generating more than $8 billion in annual revenues. Earlier in his career, he spent 20 years at the company in various commercial leadership roles.

Mr. Yang currently serves on the board of Ionis Pharmaceuticals (Nasdaq: IONS) and The Scintillon Institute. Mr. Yang holds a Bachelor of Science degree in Business Administration and Marketing from San Diego State University.